{"id":"general-corticotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Osteoporosis"},{"rate":null,"effect":"Immunosuppression / increased infection risk"},{"rate":null,"effect":"Cushingoid features"},{"rate":null,"effect":"Mood disturbances"}]},"_chembl":{"chemblId":"CHEMBL5878815","moleculeType":null,"molecularWeight":"396.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Corticosteroids bind to glucocorticoid receptors in the cytoplasm, translocate to the nucleus, and modulate gene expression to decrease production of pro-inflammatory cytokines, reduce immune cell proliferation and migration, and stabilize cell membranes. This broad immunosuppressive and anti-inflammatory effect makes corticosteroids useful across multiple therapeutic areas, though their non-selective mechanism also contributes to significant adverse effects with prolonged use.","oneSentence":"General corticotherapy suppresses immune and inflammatory responses through glucocorticoid receptor activation, reducing inflammation and modulating immune cell function.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:53.759Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and autoimmune conditions (specific indication under investigation in phase 3 trial not specified)"}]},"trialDetails":[{"nctId":"NCT00784589","phase":"PHASE3","title":"Comparison Between Rituximab Treatment and General Corticotherapy Treatment in Patients With Pemphigus","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2009-07","conditions":"Pemphigus Disease","enrollment":90},{"nctId":"NCT02841332","phase":"NA","title":"Multimodal Imaging Analysis During Treatment With Bevacizumab in Patients With Recurrent Glioblastoma","status":"TERMINATED","sponsor":"University Hospital, Toulouse","startDate":"2013-05","conditions":"Glioblastoma","enrollment":6},{"nctId":"NCT00882128","phase":"","title":"Evaluation of the Control Level of Asthmatic Patients With Seasonal Increase of Respiratory Symptoms (High and/or Low)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-05","conditions":"Asthma, Respiratory Symptoms","enrollment":3300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":36,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"General Corticotherapy","genericName":"General Corticotherapy","companyName":"University Hospital, Rouen","companyId":"university-hospital-rouen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"General corticotherapy suppresses immune and inflammatory responses through glucocorticoid receptor activation, reducing inflammation and modulating immune cell function. Used for Inflammatory and autoimmune conditions (specific indication under investigation in phase 3 trial not specified).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}